Skip to main content
KBS_Icon_questionmark link-ico
Bush House columns ;

Connecting the dots in brain research

King’s alum Patrick Brannelly (Applied Neuroscience MSc, 2022) is the founding CEO of The 10,000 Brains Project, a philanthropic initiative that supports the ethical and inclusive use of artificial intelligence in the development of better treatments for Alzheimer’s and other neurodegenerative disorders. We spoke to Patrick about balancing study with a demanding career, why leadership matters as much as scientific expertise and how King’s helped inform his vision for the future of brain health.

FEN 8 780 x 440
‘We’re pursuing a future where someone at risk of a neurodegenerative condition can receive care that is tailored to their unique biology,’ says Patrick Brannelly

What attracted you to study neuroscience at King’s?

I’d been working in neurodegeneration research for many years as a programme manager, overseeing one of the most advanced and well-funded research consortia in the world. But I felt I was missing some of the scientific depth that my colleagues and advisors brought to discussions. I wanted to become a stronger thought partner and leader, and that meant developing a deeper understanding of the science behind the research.

King’s stood out due to its global reputation in neuroscience research. The taught MSc was designed to be rigorous but flexible to accommodate each person’s specific interests, which was exactly what I was seeking.

What’s your favourite memory from your time at King’s?

Without question, working on my synoptic project with Professor Brenda Williams. Her knowledge, experience and willingness to challenge my thinking pushed me to refine my research questions and strengthen my analysis. It gave me real insight into how academic neuroscientists work and think.

I learned a tremendous amount, but it was also genuinely enjoyable.

What’s the key skill or lesson you learnt at King’s?

My synoptic project explored how the field could move towards personalised medicine for Alzheimer’s disease and related dementias. I examined the scientific evidence, emerging technologies and opportunities for using advanced data science to better understand different patient populations at each stage of their disease. If you look at the roadmap we follow at 10,000 Brains, many of those ideas trace directly back to the work I began at King’s.

The MSc gave me the confidence to take on a broader leadership role. More importantly, the research I conducted during my project directly informed the scope of the organisation I lead today.

What was your plan when you left King’s?

I knew that I wanted to work at the intersection of innovation and neuroscience. When I started at King’s, I was working at the Rainwater Charitable Foundation in the US. During my studies, I moved to Gates Ventures, where I helped to scale up the Alzheimer’s Disease Data Initiative. Then, about a year after graduating, I was approached to help launch 10,000 Brains.

I chose this career path because I wanted to work in an area where there would be 50 years of innovation ahead of me. I knew that I was a highly entrepreneurial person, but I also wanted to wake up every day feeling good about the direct social impact of the work I was doing. The King’s MSc deepened my skill set and positioned me for greater impact within the field.

What does 10,000 Brains want to achieve?

Our ambition is to use recent advances in data science to move neuroscience into a new era where personalised medicine can become a practical reality.

Neurodegenerative diseases may be the most complex challenge in medical research. In this context, artificial intelligence is an especially intriguing solution to our lack of progress to date. At 10,000 Brains, we’re bringing together these technical advances and novel international collaborations to generate new insights from vast amounts of biological and clinical data. The goal is to understand why diseases affect people differently and use that knowledge to develop more targeted diagnostics and treatments.

We’re pursuing a future where someone at risk of a neurodegenerative condition can receive care that is tailored to their unique biology, leading to earlier diagnoses, better outcomes and ultimately more lives saved.

Why do you believe neuroscience needs this new approach?

The sad reality is that no one has ever been cured of a neurodegenerative disease.

Neurological conditions have traditionally been studied in separate silos, but we now know there are considerable overlaps among neurodegenerative diseases and that these disorders can differ depending on each person’s genetics, gender, environmental exposures and stage of disease.

By sharing large, human-derived datasets, technology infrastructure and data science expertise across traditional boundaries, we can gain a more complete understanding of what is happening in each person’s brain and develop more effective treatments for them.

Artificial intelligence plays a major role in your work. Where do you see the greatest potential?

AI is transforming every stage of biomedical research – from basic science to drug discovery and clinical care.

For example, we’re part of a coalition that is developing AI-based lab assistants for neurodegeneration research. Using these tools, data analysis and interpretation that normally takes a research team months can now be done in about 10 minutes.

Other teams are using AI to transform drug discovery, allowing researchers to explore trillions of potential drug candidates, design new compounds and predict which are most likely to work.

And the impact extends to clinical care, from helping doctors document visits to improving clinical trials.

Ultimately, I believe AI will help us to move towards personalised medicine, matching individuals with the combination of treatments most likely to benefit them at each stage of disease. While concerns about AI are understandable, its potential to improve and save lives is enormous.

What advice would you give current King’s students and alumni wanting to follow in your footsteps?

Build a strong scientific foundation, but don’t stop there. The challenges facing neuroscience today require more than technical expertise. They also require leadership: the ability to step back, see the bigger picture, identify what is missing and bring people together around a shared vision.

Our field is full of profoundly talented, hard-working people. We need more leaders who can partner with them to connect big ideas, cross-functional teams and different organisations in ways that accelerate progress.

If you can combine scientific knowledge with that broader perspective, you have the opportunity to make a real difference.

 

Latest news